There were 1,794 press releases posted in the last 24 hours and 399,719 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image